​3451 Vincent Road Ste C, Pleasant Hill, CA 94523

Strategic Vaccines

A public private partnership

Strategic Vaccines LLC is a public private partnership to test and deploy FLOVID-20, an inhaled treatment for COVID-19 designed to keep COVID positive patients out of the hospital.

 

About Strategic Vaccines

A solution after diagnosis

Targeted immunotherapy is a medical breakthough that can offer doctors a solution after receiving a positive test for SARS COVID-2. 

Watch the video below to learn more about the gap in options between vaccination and treatment.

Currently Manufacturing in Solon, Ohio

Our goal is to prevent those infected with SARS COVID-2 from progressing to the serious consequences of COVID-19. Our vaccine is currently being manufactured at Oakwood Laboratories, and we’re looking into clinical studies in Cleveland.

Proven effective

Tested at the Galveston National Laboratory, we were able to prevent pneumonia in infected primates by first giving them the vaccine by inhalation.

Watch the video below to see how we’ll use T-Cell Vaccine to deliver FLOVID-20 as a treatment post-diagnosis.

The T-Cell Vaccine in detail

The T-Cell vaccine delivery platform offers a unique solution in identifying and destroying infected cells, and may be used after the patient has been infected.

Watch the video below to learn more about how the T-Cell vaccine delivery platform works.

The COVID-19 Diagnosis and Treatment Path

  • Pre-Diagnosis

    Vaccine development

    Priority funding is going into developing a vaccine that can be distributed to an uninfected subject.

  • Contracted SARS COVID-2

    Opportunity for FLOVID-20

    Currently, there are no options for a patient that has been diagnosed, but is still healthy and doesn’t require hospitalization.

  • COVID-19 Hospitalization

    Hospitalization and Therapy

    Priority funding is going into developing therapies once the patient is in urgent care.

Pre-diagnosis

Vaccine development

Priority funding is going into developing a vaccine that can be distributed to an uninfected subject.

Contracted SARS COVID-2

Opportunity for FLOVID-20

Currently, there are no options for a patient that has been diagnosed, but is still healthy and doesn’t require hospitalization.

COVID-19 Hospitalization

Hospitalization and Therapy

Priority funding is going into developing therapies once the patient is in urgent care.

Founding companies

Home

Partner companies

Contact us for more information